肥胖降低了原发性痛风患者的尿酸降低功效:一项前性队列研究
Zan Cheng1,2,3, Xinmiao Xu4, Han Qi1,2
1Shandong Provincial Clinical Research Center for Immune Diseases and Gout, the Affiliated Hospital of Qingdao University, Qingdao, China.
Rheumatology (Oxford, England)
|February 10, 2025
概括
肥胖症显著降低了对于痛风患者的费布斯塔特的有效性. 超重个体对正常体重患者的反应类似,表明肥胖是影响尿酸降低疗法 (ULT) 成功的关键因素.
科学领域:
- 类风湿病学 类风湿病学
- 代谢障碍 代谢障碍 代谢障碍
- 药物治疗 药物治疗
背景情况:
- 在痛风患者中,肥胖很普遍 (53%).
- 肥胖对尿酸降低疗法 (ULT) 疗效的影响尚不清楚.
- 这项研究调查了男性痛风患者在不同体质指数 (BMI) 类别中的febuxostat反应.
研究的目的:
- 为了比较febuxostat在男性痛风患者的疗效与正常,超重和肥胖的BMI.
- 确定BMI与达到尿酸水平目标之间的关系.
- 评估在ULT期间与BMI相关的痛风爆发的发生率.
主要方法:
- 对633名男性痛风患者的前性研究,按BMI分层.
- 基线特征 (年龄,疾病持续时间,SU) 匹配.
- 费布克索斯塔特治疗 (20-40毫克/天) 持续12周.
- 使用了考克斯回归和受限立方线 (RCS) 分析.
主要成果:
- 肥胖患者获得的SU<6.0 mg/dl (38.9%) 显着较低,而超重患者 (54.2%) 和正常体重患者 (63.8%) 则相比较低.
- 高BMI独立预测了实现SU目标的可能性较低 (HR=0.92).
- 肥胖和超重群体表现出高于正常体重个体的痛风发作发病率.
结论:
- 肥胖,而不是超重,在男性痛风患者中显著降低了febuxostat的疗效.
- 较高的BMI是ULT效率降低和痛风发作增加的危险因素.
- 对肥胖的痛风患者可能需要量身定制的治疗策略.
相关概念视频
Oral Hypoglycemic Agents: Biguanides and Glitazones
132
Biguanides, particularly metformin (Glucophage), are insulin sensitizers that enhance glucose uptake, thereby reducing insulin resistance. Unlike sulfonylureas, metformin doesn't prompt insulin secretion, which helps to curb hypoglycemia risk. Metformin is beneficial in treating conditions like polycystic ovary syndrome due to its insulin-resistance reduction capability. The drug's primary action involves curtailing hepatic gluconeogenesis, a significant contributor to high blood...
132
Antihypertensive Drugs: Action of Diuretics
569
Diuretics are antihypertensive drugs used to treat hypertension resulting from sodium and water retention. Sodium, vital for fluid balance and nerve or muscle function, is regulated by the kidneys through millions of nephrons. Blood enters nephrons via afferent arterioles, which branch into capillaries called glomeruli. These filter blood plasma, allowing water and solutes, like sodium ions, to pass through capillary walls into Bowman's capsule. The filtrate then flows through various...
569
Oral Hypoglycemic Agents: Sulfonylureas
153
Sulfonylureas are oral hypoglycemic agents utilized in treating type 2 diabetes. They are characterized by their unique sulfonylurea chemical structure. The family of sulfonylureas is divided into generations. First-generation sulfonylureas, including tolbutamide (Orinase), chlorpropamide (Diabinese), and tolazamide (Tolinase), trigger insulin release from pancreatic β cells and enhance peripheral tissues' insulin sensitivity. The second-generation members, such as glipizide...
153
Oral Hypoglycemic Agents: α-Glucosidase Inhibitors
105
α-glucosidase inhibitors, including acarbose (Precose), miglitol (Glyset), and voglibose (Voglib) (primarily available in Asia), are drugs that control blood sugar levels by delaying the digestion of starch and disaccharides. They achieve this by inhibiting α-glucosidase enzymes in the intestine, which slow the absorption of carbohydrates in the intestine, which in turn leads to a prolonged release of the glucoregulatory hormone GLP-1 from intestinal L-cells.
Acarbose and miglitol are...
Acarbose and miglitol are...
105
Peptic Ulcer Disease IV: Management
45
Medical treatment strategies for peptic ulcers encompass various methods. The primary goal of treatment is to diminish gastric acidity and strengthen mucosal defense mechanisms.
The therapeutic approach involves ensuring adequate rest, implementing drug therapy, promoting smoking cessation, making dietary modifications, and emphasizing long-term follow-up care.
Pharmacological management
The prevailing therapy for peptic ulcers involves a combination of managing the patient's current...
The therapeutic approach involves ensuring adequate rest, implementing drug therapy, promoting smoking cessation, making dietary modifications, and emphasizing long-term follow-up care.
Pharmacological management
The prevailing therapy for peptic ulcers involves a combination of managing the patient's current...
45
Dipeptidyl Peptidase 4 Inhibitors
117
Dipeptidyl peptidase 4 (DPP-4) is a serine protease widely distributed in the body. It's involved in the inactivation of GLP-1 and GIP hormones, which are crucial for insulin regulation. DPP-4 inhibitors, such as sitagliptin (Januvia), saxagliptin (Onglyza), linagliptin (Tradjenta), alogliptin (Nesina), and vildagliptin (Galvus), help increase the proportion of active GLP-1, enhancing insulin secretion. These inhibitors work by competitively binding to DPP-4. This binding causes a...
117


